TFPI2 and neoplasm: In vivo, TFPI2 overexpression significantly reduced tumor volume and size in sorafenib-treated mice (Figure 6C), consistent with a higher proportion of PARP-positive and TUNEL-positive cells and lower Ki67 expression (Figure 6D-E), indicating enhanced sorafenib-induced apoptosis in TFPI2-overexpressing cells.